Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343939 · ClinicalTrials.gov registry record · Phase 1
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT02343939: Clinical Trial Phase 1 study, sponsored by Gilead Sciences.
NCT02343939 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 148 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02343939, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
Primary Outcome
DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment. DLT assessment was applicable only for Phase 1b and Phase 2 safety run-in participants.
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Entospletinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
Why NCT02343939 stopped before completion
NCT02343939 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 5 interventions - of which Azacitidine is the first listed.
NCT02343939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02343939 about?
NCT02343939 is a clinical study titled "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)". This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
What is the current status of trial NCT02343939?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2015-07-01. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT02343939?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Entospletinib (DRUG).
Who is sponsoring clinical trial NCT02343939?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02343939's enrollment target sits among peer trials
148 382nd of 2000 higher than 1,614 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI